Decipher Genomics Resource Information Database

Observational study involving the release of genome-wide expression data allowing
participating institutions to pair these data with clinical treatment and outcome data for
patients in whom Decipher testing was performed. Through these collaborations, the GRID
database population will be used to characterize the genomics of cancer and discover new gene
expression signatures that may be useful for expanding the current understanding of the
biology of the disease.

Inclusion Criteria:

Decipher Post-Op Clinical Indications

- Patient must have achieved initial PSA nadir (defined as undetectable PSA of

≤0.1 ng/mL) within 4-6 weeks, and

- Pathological stage T2 disease with a positive surgical margin, or

- Pathological stage T3 disease (e.g., extraprostatic extension, seminal vesicle
invasion, bladder neck invasion), or

- High Preoperative PSA (e.g., PSA ≥20 ng/mL), or

- High Gleason grade disease (e.g., Gleason 7 to 10 or Tertiary Gleason pattern 5), or

- Perineural, lymphovascular invasion, or

- Lymph node involvement, or

- Rising PSA or Biochemical Recurrence

Decipher Biopsy Clinical Indications

• Any patient diagnosed with localized prostate cancer and assessed as being very low, low,
intermediate or high risk by NCCN guidelines:

1. Very low risk: T1c, Gleason score ≤ 6, PSA < 10ng/mL, fewer than 3 prostate biopsy
cores positive,

- 50% cancer in any core, PSA density <0.15 ng/mL/g

2. Low risk: T1-T2a, Gleason score ≤ 6, PSA < 10ng/mL

3. Intermediate risk: T2b-T2c, Gleason score 7, or PSA 10-20 ng/mL

4. High risk: T3a, or Gleason score 8-10, or PSA > 20 ng/mL

Exclusion Criteria:

1. Diagnosed with metastatic disease (M1)

2. Metastatic Disease (M+) prior to surgery

3. For salvage setting patients: Metastatic Disease (M+) at PSA rise

4. Received any neo-adjuvant prostate cancer treatment before radical prostatectomy

5. Required patient clinical data is not available for evaluation of eligibility criteria

6. Any other medical condition that the treating physician,study investigators or
designee determines should exclude the subject from the study